A08-Respuesta Inmune y Cáncer
Oncología / IBS-A08
El grupo está involucrado en el análisis de la respuesta inmunitaria en el cáncer, el papel de los leucocitos infiltrantes y las características inmunofenotípicas de las células tumorales. El grupo de investigación ha identificado los principales mecanismos de escape que utilizan los tumores (cáncer renal, vejiga, próstata y colon) para eludir la respuesta inmunitaria. Particularmente se ha centrado en aquellos mecanismos que impiden el reconocimiento antigénico por los efectores citotóxicos inmunitarios. Se han evaluado los aspectos más relevantes que estos defectos tienen en diversos protocolos de inmunoterapia y la corrección posible, mediante procedimientos de terapia génica. El grupo colabora con diversos centros europeos y americanos que trabajan en el diseño de vacunas contra el cáncer
Palabras clave
Escape Inmunológico del Cáncer, Inmunoterapia, Terapia Génica
HERNANI GIL JULIO
JOSE RAMON VILCHEZ GUTIERREZ
ANA BELEN RODRIGUEZ MARTIN
VERONICA SANZ SERRANO
IRENE DIAZ ALVEROLA
MARIA JOSE OLIVARES DURAN
ANTONIO RODRIGUEZ NICOLAS
TERESA RODRIGUEZ RUIZ
JOSE MARIA ROMERO NOGUERA
FRANCISCO RUIZ-CABELLO OSUNA
FERNANDO VAZQUEZ ALONSO
FRANCISCO JAVIER VICENTE PRADOS
NATALIA APTSIAURI
MONICA BERNAL SANCHEZ
JOSE MANUEL COZAR OLMO
ANGEL MIGUEL GARCIA LORA
JUAN FRANCISCO GUTIERREZ BAUTISTA
PILAR JIMENEZ GAMIZ
FRANCISCO JAVIER PEREA GARCIA
PER ANDERSON
Clinical Case: Patient with Mixed Graft Rejection Four Days after Kidney Transplantation Developed Specific Antibodies against Donor Bw4 Specificities
ANTIBODIES, 2021;
Biofabrication of a Tubular Model of Human Urothelial Mucosa Using Human Wharton Jelly Mesenchymal Stromal Cells
POLYMERS, 2021;
FI:4,329; Q1
Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer
CANCERS, 2021;
FI:6,639; Q1
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
CANCERS, 2021;
FI:6,639; Q1
Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study
ACTAS UROLOGICAS ESPANOLAS, 2021;
FI:0,994; Q4
Genetic variants in xenobiotic detoxi fication enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer
SCIENCE OF THE TOTAL ENVIRONMENT, 2020;
FI:6,551; D1
Dietary Diversity and Prostate Cancer in a Spanish Adult Population: CAPLIFE Study
NUTRIENTS, 2020;
FI:4,546; Q1
GARP is a key molecule for mesenchymal stromal cell responses to TGF-beta and fundamental to control mitochondrial ROS levels
STEM CELLS TRANSLATIONAL MEDICINE, 2020;
FI:6,429; Q1
GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta
CELL DEATH & DISEASE, 2020;
FI:6,304; Q1
Frequent Microalgae in the Fountains of the Alhambra and Generalife: Identification and Creation of a Culture Collection
APPLIED SCIENCES-BASEL, 2020;
FI:2,474; Q2
The role of miRNAs as biomarkers in prostate cancer
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2019;
FI:6,081; D1
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
ANNALS OF SURGICAL ONCOLOGY, 2019;
FI:3,681; Q1
The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition
NUTRIENTS, 2019;
FI:4,171; Q1
MHC Class-I Loss and Cancer Immune Escape Introduction
MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;
FI:2,126; Q2
MHC/HLA Class I Loss in Cancer Cells
MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;
FI:2,126; Q2
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
CURRENT OPINION IN IMMUNOLOGY, 2018;
FI:7,932; D1
Genetic markers a landscape in prostate cancer
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2018;
FI:5,205; D1
MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy
FRONTIERS IN IMMUNOLOGY, 2018;
FI:5,511; Q1
The influence of nutritional factors on prostate cancer incidence and aggressiveness
AGING MALE, 2018;
FI:2,5; Q2
HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15
IMMUNOGENETICS, 2018;
FI:2,094; Q3
Assessing robot-assisted laparoscopic prostatectomy
LANCET, 2017;
FI:47,831; D1
Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017;
FI:5,133; D1
Rejection versus escape: the tumor MHC dilemma
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017;
FI:4,711; Q1
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration
INTERNATIONAL JOURNAL OF CANCER, 2017;
FI:6,513; Q1
Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness
PLOS ONE, 2017;
FI:2,806; Q1
Penile Strangulation Caused by a Seal Ring
ARCHIVES OF SEXUAL BEHAVIOR, 2016;
FI:2,704; D1
The urgent need to recover MHC class I in cancers for effective immunotherapy
CURRENT OPINION IN IMMUNOLOGY, 2016;
FI:7,126; D1
Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;
FI:4,846; Q1
Redefining cancer immunotherapy-optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27-30, 2015, Ljubljana, Slovenia
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;
FI:4,846; Q1
Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype
INTERNATIONAL JOURNAL OF CANCER, 2016;
FI:5,531; Q1
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
ONCOTARGET, 2015;
FI:6,359; D1
Epithelial cancer biomarker EpCAM determination in peripheral blood samples using a microfluidic immunosensor based in silver nanoparticles as platform
SENSORS AND ACTUATORS B-CHEMICAL, 2015;
FI:4,097; D1
Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort
PLOS ONE, 2015;
FI:3,234; Q1
Prognostic role of genetic biomarkers in clinical progression of prostate cancer
EXPERIMENTAL AND MOLECULAR MEDICINE, 2015;
FI:3,446; Q2
The Role of Toll-Like Receptor Polymorphisms in Acute Pancreatitis Occurrence and Severity
PANCREAS, 2015;
FI:2,959; Q2
La latencia en el proceso metastásico como una nueva estrategia para destruir las células cancerosas
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI15/00528
Tiempo de ejecución: 01/01/2016 - 31/12/2018
IP: ANGEL MIGUEL GARCIA LORA
Alteración de la presentación antigénica en las células tumorales: Implicadas en la inmunovigilacia e inmunoterapia.
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI17/00197
Tiempo de ejecución: 01/01/2018 - 31/12/2020
PI18/00826 – MHC clase I e inmunoescape en cáncer colorrectal: Evaluación del valor diagnóstico de exosomas/cfDNA y estudio del papel del estroma tumoral
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI18/00826
Tiempo de ejecución: 01/02/2019 - 31/12/2021
IP: PER ANDERSON
Descifrando como el sistema inmune controla a las células cancerosas
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI19/01179
Tiempo de ejecución: 01/01/2020 - 31/12/2022
IP: ANGEL MIGUEL GARCIA LORA
Estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico. DAROL
Financiador: BAYER HISPANIA S.L.
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTOS DE SEGUIMIENTO PROSPECTIVO
Tiempo de ejecución: 03/12/2021 - 30/09/2026
IP: FERNANDO VAZQUEZ ALONSO
Estudio observacional sobre el manejo en la practica clinica del cancer de prostata resistente a la castracion con estatus metastasico desconocido (AFRODITA)
Financiador: JANSSEN-CILAG, S.A.
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 23/12/2019 - 30/04/2021
IP: FERNANDO VAZQUEZ ALONSO
